Profile of abemaciclib and its potential in the treatment of breast cancer

about

Profile of abemaciclib and its potential in the treatment of breast cancer

Item

http://www.wikidata.org/entity/Q57107448

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Profile of abemaciclib and its potential in the treatment of breast cancer

@en

Profile of abemaciclib and its potential in the treatment of breast cancer

@nl

type

Item

label

Profile of abemaciclib and its potential in the treatment of breast cancer

@en

Profile of abemaciclib and its potential in the treatment of breast cancer

@nl

prefLabel

Profile of abemaciclib and its potential in the treatment of breast cancer

@en

Profile of abemaciclib and its potential in the treatment of breast cancer

@nl

P1476

Profile of abemaciclib and its potential in the treatment of breast cancer

@en

P2093

James M Martin

http://www.w3.org/2001/XMLSchema#string

Lori J Goldstein

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Comprehensive molecular portraits of human breast tumours

Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.

Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

Cyclin D1 in breast cancer

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

P304

5253-5259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S149245

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30214230

http://www.w3.org/2001/XMLSchema#string

P932

6120573

http://www.w3.org/2001/XMLSchema#string